Hexa Health Benefits
Trusted Doctors and Top Hospitals
Consultations with expert surgeons
Extensive assistance throughout your treatment
Table of Contents
Book Consultation
The human immune system is capable of recognising and precisely reacting to invasive infections. By mediating both specificity and memory, lymphocytes (a type of white blood cell) are crucial to the adaptive immune response. But, uncontrolled production of lymphocytes can lead to lymphoproliferative disorders (LPDs).
This article will provide each and every detail regarding chronic lymphoproliferative disorders, their causes, risk factors, symptoms, prevention, diagnosis, treatment, and much more. So read on!
Disease Name | Lymphoproliferative Disorders (LPDs) |
Symptoms | Enlarged lymph nodes, Fatigue, Unexplained tiredness, Unintentional weight loss, Night sweats |
Causes | Genetic mutation, Age, Family history, Chemical exposure, Environmental factors |
Diagnosis | Physical examination, Medical history, Genetic testing, Bone marrow biopsy |
Treated by | Haemato-oncologist |
Treatment Options | Chemotherapy |
Lymphoproliferative disorders (LPDs) are a group of ailments that are mainly identified by the abnormal growth and proliferation of lymphocytes, which are a type of white blood cell involved in the immune response. LPDs can affect both B cells and T cells, the two main types of lymphocytes in the body.
Notably, lymphocytes play a crucial role in the body's defence against infections and diseases. However, in LPDs, the normal control mechanisms that regulate the growth and division of lymphocytes become disrupted, leading to uncontrolled and excessive proliferation of these cells.
Besides, LPDs can be broadly classified into two main categories: benign (non-cancerous) and malignant (cancerous) disorders. Benign LPDs often occur as a reaction to infections, inflammation, or certain medications and are usually temporary. Malignant LPDs, on the other hand, involve the development of cancerous lymphocytes that can spread to other parts of the body.
Further, lymphoproliferative disorders may lead to:
Monoclonal lymphocytosis
Lymphadenopathy
Swollen lymph nodes
Bone marrow infiltration
Interruption of regular bone marrow blood cell formation
Lymphoproliferative disorders are a broad category that includes numerous diseases. Each subtype has its distinct characteristics, including specific cell types involved, clinical behaviours, and treatment approaches.
B cell lymphoproliferative disorder cancers include:
B Cell Chronic Lymphocytic Leukaemia: It is a type of cancer characterised by the amassing of abnormal and mature B cells in the blood, bone marrow, and lymphoid tissues.
B Cell Prolymphocytic Leukaemia: The condition is a very rare form of leukaemia marked by the build-up of aberrant B lymphocytes in the blood, bone marrow, lymph nodes, and other tissues.
Non-Hodgkin’s Lymphoma: It is a low-grade B-cell lymphoproliferative disorder that originates in the lymphatic system. It is characterised by the abnormal growth and proliferation of lymphocytes.
Hairy Cell Leukaemia: This is a slow-growing type of cancer characterised by the excessive accumulation of abnormal B lymphocytes (hairy cells) in the bone marrow, leading to a decrease in healthy blood cells.
Splenic Lymphoma with Villous Lymphocytes: It is a rare type of lymphoproliferative disorder that primarily affects the spleen. It is characterised by the presence of abnormal lymphocytes with villous projections on their surface.
T cell disorders include:
Sezary Syndrome: It is a rare and aggressive form of cutaneous T cell lymphoma (CTCL), a type of non-Hodgkin lymphoma. It primarily affects the skin but can involve other organs as well.
T Cell Prolymphocytic Leukaemia: T cell prolymphocytic leukaemia (T-PLL) is a rare and aggressive form of blood cancer characterised by the overgrowth of mature T lymphocytes (T cells) in the blood, bone marrow, and various organs.
Adult T Cell Leukaemia-Lymphoma: Adult T cell leukaemia-lymphoma (ATLL) is a rare and aggressive type of blood cancer that is caused by the human T cell lymphotropic virus type 1 (HTLV-1).
Large Granular Lymphocyte Leukaemia: Aggressive natural killer cell leukaemia (ANKL) is a rare and aggressive form of leukaemia that arises from the abnormal proliferation of natural killer (NK) cells, a type of immune cell.
Natural Killer Cell Disorders include:
Aggressive Natural Killer Cell Leukaemia: It is a rare and highly aggressive form of leukaemia that involves the rapid proliferation of abnormal natural killer cells in the bone marrow and peripheral blood.
Chronic Lymphoproliferative Disorders of Natural Killer Cells: They are a group of rare haematological disorders characterised by the clonal expansion of abnormal NK cells. These disorders include chronic lymphoproliferative disorder of NK cells and aggressive NK cell leukaemia.
Depending on the type of the condition, the symptoms vary from patient to patient. The symptoms of lymphoproliferative diseases are as follows:
Enlarged lymph nodes
Fatigue
Unexplained tiredness
Unintentional weight loss
Night sweats
Recurrent infections
Bone pain
Abdominal pain or discomfort
Headache
Seizures
Anaemia
Easy bruising or bleeding
Expert Doctors (10)
NABH Accredited Hospitals (10)
When the mechanisms governing the growth of lymphocytes collapse, lymphoproliferative diseases appear. For some forms of lymphoproliferative diseases, researchers have pinpointed particular risk factors, but frequently the root cause is unknown.
The causes of lymphoproliferative disorders are as follows:
X-linked Lymphoproliferative Disorder: The X chromosomal mutation that causes T cell and natural killer cell lymphoproliferative disorders is the cause of the condition known as X-linked lymphoproliferative disorder. It makes the immune system hypersensitive to the Epstein-Barr virus, which is thought to affect more than 90% of people globally.
Autoimmune Lymphoproliferative Syndrome: A mutation in the genes that govern lymphocytes results in autoimmune lymphoproliferative syndrome. Even when there is no infection present, the immune systems of those who have this disease take long to recover.
Post-transplant Lymphoproliferative Disorder: Immunosuppression following an organ transplant is the cause of the condition known as post-transplant lymphoproliferative disease.
There are some risk factors that have been linked to their growth. Recognizing those who could be at a higher risk and taking preventive steps can be made easier with an understanding of these risk factors. Some typical risk factors for lymphoproliferative diseases are listed below:
Age: Certain types, such as non-Hodgkin lymphoma, tend to occur more frequently in older individuals, while others, like Hodgkin lymphoma, have a bimodal age distribution, affecting both young adults and older individuals.
Weakened Immune System: LPDs are more likely to develop in people with compromised immune systems, such as those with HIV/AIDS, organ transplant patients taking immunosuppressive medications, or people with specific autoimmune disorders.
Genetic Factors: A few chromosomal defects or specific genetic mutations have been connected to certain lymphoproliferative diseases. For instance, having a genetic abnormality like Down syndrome increases the risk of getting lymphoma or leukaemia.
Environmental Factors: The risk of LPDs may rise in response to exposure to specific environmental elements and substances including radiation, pesticides, or infections like the Epstein-Barr virus that are linked to lymphoma.
Family History: The likelihood of acquiring LPDs may be increased by a family history of these conditions. Families may share environmental exposures and genetic risk factors, which can raise the risk.
Unfortunately, there are no proven ways to reduce the risk of contracting this illness. While it may not be possible to completely prevent lymphoproliferative disorders, there are some general strategies that can help reduce the risk of developing LPDs. Here are some preventive measures that may be beneficial:
Medical Check-ups: Routine check-ups with a healthcare provider can help detect any abnormalities or early signs of lymphoproliferative disorders. It is important to follow the recommended screening guidelines and undergo necessary tests or imaging as advised by the healthcare professional.
Healthy Lifestyle Choices: Adopting a healthy lifestyle can have a positive impact on overall health and potentially reduce the risk of developing lymphoproliferative disorders.
Immunisation: Vaccinations against viruses like the Epstein-Barr virus (EBV) and human papillomavirus (HPV) can help lower the risk of developing these disorders.
Avoidance of Environmental Carcinogens: Reducing exposure to environmental factors that are known to increase the risk of lymphoproliferative disorders can be beneficial. This may involve avoiding exposure to certain chemicals, toxins, radiation, and other known carcinogens whenever possible.
Generally, a physical examination and consideration of the patient’s medical and family histories mark the beginning of the diagnostic procedure. Blood tests may be recommended by the healthcare professional to look for indicators of certain blood conditions or viruses like cytomegalovirus or Epstein-Barr virus. Additionally, blood testing may be done to search for genes linked to certain illnesses.
Finding tumours or other disease symptoms can be aided by imaging techniques that include:
X-rays
Bone scans
Ultrasound
CT scan
MRI scan
Biopsies, or little tissue samples, are required to confirm the diagnosis of many different forms of blood cancers. It may require a biopsy of the following things, depending on the cancer:
Bone marrow
Lymph nodes
Internal organs like the spleen
Preparing for a doctor's consultation for lymphoproliferative disorders can help ensure that patients make the most of their appointment and effectively communicate their concerns and questions. Here are some tips to help them prepare:
Make a list of all the symptoms, noting their onset date, duration, frequency, and any aggravating or mitigating circumstances.
Write down any inquiries or worries that one may have regarding his/her health, available therapies, outlook, and lifestyle changes. This makes it easier to recall everything during the consultation.
Gather all pertinent medical information, such as test results, imaging reports, pathology reports, and records of prior treatments. The doctor will have a thorough awareness of the patient's medical history with the help of this information, which will be beneficial during evaluation.
The treatment of lymphoproliferative disorders depends on several factors, including the specific type and stage of the disease, the patient's overall health, and individualised treatment goals. Here are some common treatment options for lymphoproliferative disorders:
Chemotherapy: Chemotherapy uses chemicals to destroy cancer cells and stop them from proliferating. For some lymphoproliferative illnesses, it can be given intravenously, orally, or directly into the cerebrospinal fluid.
Radiation Therapy: High-energy beams are used in radiation therapy to target and kill cancer cells. It can be used either alone or in conjunction with other therapies to reduce tumours, ease symptoms, or stop the spread of cancer.
Immunotherapy: Immunotherapy encourages the immune system to identify and combat cancer cells. Examples of immunotherapeutic strategies used to treat lymphoproliferative diseases include monoclonal antibodies, immune checkpoint inhibitors, and CAR-T cell therapy.
Targeted Therapy: Targeted therapy drugs specifically target certain molecules or genetic mutations in cancer cells, disrupting their growth signals. These therapies are designed to minimize harm to healthy cells and can be effective in certain types of lymphoproliferative disorders.
Stem Cell Transplantation: For some lymphoproliferative illnesses, stem cell transplantation, sometimes referred to as bone marrow transplantation, may be advised. In order to reestablish regular blood cell production, sick or injured bone marrow is replaced with healthy stem cells.
Supportive Care: Supportive care practises are crucial in managing lymphoproliferative diseases in addition to specialised therapies. As well as psychological and emotional support, this may involve drugs to control infection, treat side effects, and manage pain.
The cost of LPD treatment in India is generally influenced by several factors including the type of LPD, the stage of LPD, the treatment modality used, the patient’s age, patient’s comorbidities, the type and location of the hospital, doctor’s expertise, insurance coverage and much more.
To know the exact cost of the LPD treatment in India, one must need to consult their healthcare provider. However, the table below also provides the approximate cost of the LPD treatments.
Treatment Options | Cost Estimate Range |
Chemotherapy | ₹ 75,000 to ₹ 2,50,000 |
Radiation therapy | ₹ 60,000 to ₹ 2,00,000 |
Immunotherapy | ₹ 80,000 to ₹ 2,25,000 |
Targeted Therapy | ₹ 80,000 to ₹ 2,25,000 |
Stem Cell Transplant | ₹ 15,00,000 to ₹ 27,00,000 |
Depending on the precise type and stage of the disease, as well as the patient's condition, the survival rate for lymphoproliferative disorders might vary significantly. It's crucial to keep in mind that survival rates are estimations based on sizable patient populations and may not precisely predict the prognosis for a particular patient.
The severity of lymphoproliferative disorders varies greatly between diseases. For instance, there is a 64% relative 5-year survival rate for diffuse large B cell lymphoma patients. However, a study indicates that for natural killer cell leukaemia, the 1-year survival rate was less than 5%.
The following factors could affect a patient’s survival:
The type of lymphoproliferative disease the patient has
Age
His/her general health
Rate of illness progression
Specific genetic factors
The specific risks and problems can change depending on the disorder's nature and stage, as well as the patient's particular set of circumstances. Following are some general issues connected to lymphoproliferative disorders:
Developing Anaemia: Lymphoproliferative disorders can affect the production of healthy red blood cells and platelets in the bone marrow. This can lead to anaemia, characterised by a decrease in red blood cell count, resulting in fatigue, weakness, and shortness of breath. Reduced platelet count can lead to an increased risk of bleeding or easy bruising.
Thrombocytopenia: LPDs can also result in thrombocytopenia and neutropenia. Infection and haemorrhage risk can both be increased by these problems.
Weakening of the Immune System: Lymphoproliferative disorders can weaken the immune system, making individuals more susceptible to infections.
Cancer cells can crowd out normal immune cells, and certain treatments, such as chemotherapy, can further suppress the immune system. Infections can range from minor respiratory infections to more severe and life-threatening conditions.Lymphoproliferative disorders can be progressive in nature. Delaying therapy enables the condition to worsen and could result in the spread of cancer cells. This may make treatment more difficult and lessen the likelihood of long-term disease control or remission.
Delaying treatment may cause the condition could become less responsive to medication, which would make subsequent treatments less successful.
Delaying treatment can cause significant distress for patients and their families. Uncertainty, anxiety, and fear can increase as the disease progresses without intervention. Early treatment initiation may help alleviate some of these psychological burdens and provide a sense of control and hope.
It is important to see a doctor if individuals experience any concerning symptoms or if they have risk factors for lymphoproliferative disorders. If a patient has persistent symptoms such as unexplained weight loss, fatigue, night sweats, enlarged lymph nodes, or recurrent infections, it is important to consult a doctor.
These symptoms could be indicative of various conditions, including lymphoproliferative disorders. Also, if a patient notices the presence of enlarged lymph nodes that are painless, firm, and have been present for more than a few weeks, it is recommended to seek medical evaluation. The doctor can assess lymph nodes and determine if further investigation is necessary.
There is no specific diet for a person with lymphoproliferative disorders. But, patients can always try to create nourishing and well-balanced meals.
Vegetables, including broccoli, Brussels sprouts, and kale must be a part of a balanced diet. As these vegetables are abundant in nourishing plant chemicals like beta carotene, it is important to include a variety of them in the normal diet.
The anti-inflammatory properties of a plant-based Mediterranean diet can aid in preventing all forms of non-Hodgkin lymphomas. Legumes, nuts, seeds, and whole grains are all part of a plant-based Mediterranean diet.
Protein is essential for tissue repair, growth, and maintenance. Lymphoproliferative disorders can cause damage to the body's tissues. And, adequate protein intake supports the body's ability to repair and regenerate cells and tissues. Some of the popular protein sources are chicken, fish, eggs, tofu, and lentils.
People should normally consume a diet low in added sugar and highly processed foods. However, it's more crucial that patients consume enough calories if they have lymphoproliferative disorders. This will assist in preventing weight loss and preserving muscle mass while receiving treatment.
Lymphoproliferative disorders are characterised by the unchecked proliferation of lymphocytes that result in monoclonal lymphadenopathy, lymphocytosis, and bone marrow infiltration. These ailments may or may not be malignant. While some mutations may be acquired throughout a patient's life, others may be inherited from parents. Besides, the prognosis for lymphoproliferative diseases is extremely variable. While some illnesses don't need any therapy, others could be fatal.
So, discuss with healthcare practitioners if newer therapies or clinical trials could give the patient a chance to be cancer-free. And, reach out to HexaHealth to get connected with the best oncologists to battle lymphoproliferative disorders.
Suggested Reads
Types of Lymphoma |
Lymphoma Symptoms |
Is Lymphoma Curable |
Difference between Hodgkin and Non-Hodgkin Lymphoma |
Hodgkin Non Hodgkin Lymphoma Treatment |
Diffuse Large B Cell Lymphoma |
Lymphoproliferative disorders are a group of ailments characterised by an excessive proliferation of white blood cells termed lymphocytes. These illnesses frequently affect people with impaired immune systems.
There are several types of chronic lymphoproliferative disorders, including:
Non-Hodgkin lymphoma
The symptoms of lymphoproliferative diseases are as follows:
Fever
Sore throat
Swollen lymph glands
Spleen enlargement or liver enlargement
Jaundice
Elevated white blood cell count
Anaemia
Abnormal bleeding or bruising
Excessive bleeding
Unintentional weight loss
Night sweats
Loss of appetite
The causes of lymphoproliferative disorders are not fully understood, but several factors have been identified that may contribute to their development.
These factors can vary depending on the specific type of lymphoproliferative disorder. Here are some known causes and risk factors associated with lymphoproliferative disorders:
Genetic predisposition
Immune system dysfunction
Infections
Some lymphoproliferative diseases are caused by genetic abnormalities, either inherited or acquired. An altered chromosome, for instance, is present in most CLL patients.
Disorders involving lymphoproliferation are more common in people with immunodeficiency. Some conditions linked to immunodeficiency-associated lymphoproliferative disorders are as follows:
Common variable immunodeficiency
Chediak–higashi syndrome
Severe combined immunodeficiency
Wiskott-aldrich syndrome
Ataxia-telangiectasia
Invasive fungal infections
Viral infections such as HIV
Tumours or other disease symptoms can be detected by imaging techniques like:
X-rays
Bone scans
Ultrasound
CT scan
MRI scan
Further, biopsies are required to confirm the diagnosis of many different forms of blood cancers.
The overall 5-year survival rate for Hodgkin lymphoma is relatively high, with an average rate of around 86% in the United States.
However, the lymphoproliferative disorder survival rate can vary depending on the disease stage, age, and presence of certain risk factors.
Here are some common treatment modalities for lymphoproliferative disorders:
Chemotherapy
Radiation therapy
Immunotherapy
Targeted therapy
Stem cell transplantation
Surgery
The choice of the best first treatment for lymphoproliferative disorders depends on several factors, including the specific type and stage of the disease, individual patient characteristics, and other considerations.
Treatment decisions are typically made by a multidisciplinary team of healthcare professionals, including oncologists, haematologists, and radiation oncologists.
Pulmonary lymphoproliferative disorders refer to a group of conditions characterised by the abnormal proliferation of lymphoid cells within the lungs.
These disorders can range from benign or reactive lymphoid proliferations to malignant lymphomas involving the lung tissue.
A thorough medical history, physical examination, and assessment of immunodeficiency status are essential in diagnosing immunodeficiency-associated LPDs.
Evaluation of any underlying immunodeficiency condition is crucial.
Treating the underlying immunodeficiency is crucial in managing immunodeficiency-associated LPDs.
This may involve immune system reconstitution through stem cell transplantation, administration of immunoglobulin replacement therapy in primary immunodeficiency, or adjustment of immunosuppressive medications in secondary immunodeficiency.
B cell lymphoproliferative disorder (B-LPD) refers to a group of disorders characterised by the abnormal proliferation of B cells, which are a type of white blood cells involved in the immune response. B-LPDs can range from benign or reactive conditions to malignant lymphomas.
Clonal lymphoproliferative disorder refers to a condition characterised by the abnormal proliferation of a single clone of lymphocytes.
In clonal LPD, a population of lymphocytes, usually B cells or T cells, undergoes uncontrolled growth and expansion, leading to the accumulation of a single clone of cells.
Low-grade B cell lymphoproliferative disorder refers to a group of indolent (slow-growing) lymphomas or lymphoproliferative disorders involving B cells. These disorders are characterised by the accumulation of abnormal, mature B cells that proliferate slowly and have a relatively indolent clinical course.
The hallmark of lymphoproliferative disorders is the abnormal proliferation of lymphocytes. This can involve B cells, T cells, or natural killer cells, depending on the specific subtype of the disorder.
The abnormal lymphocytes can accumulate in lymphoid tissues, such as lymph nodes, spleen, and bone marrow.
Lymphoproliferative disorders span a wide spectrum, ranging from indolent (slow-growing) diseases to aggressive or highly malignant lymphomas.
Indolent lymphomas, such as follicular lymphoma or certain subtypes of chronic lymphocytic leukaemia, often have a relatively better prognosis with prolonged survival.
Lymphoproliferative disorders, particularly malignant lymphomas, can progress over time if left untreated.
The abnormal lymphocytes can continue to proliferate and accumulate, leading to an increase in tumour burden and spread to other organs or tissues.
Monoclonal antibodies are laboratory-produced antibodies that target specific proteins on cancer cells.
They can be used alone or in combination with chemotherapy. Rituximab is a commonly used monoclonal antibody in B cell lymphomas, including non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
It specifically targets the CD20 protein on B cells, leading to their destruction by the immune system.
Lymphoproliferative disorders are a diverse group of diseases characterised by uncontrolled growth of lymphocytes in the lymphatic system.
The progression of lymphoproliferative disorders can vary depending on the specific type and subtype of the disorder.
Lymphoproliferative disorders encompass a wide range of conditions, including both benign and malignant diseases of the lymphatic system.
The genetic and molecular basis of these disorders can vary significantly depending on the specific type and subtype.
Some studies have suggested associations between certain lifestyle factors and the risk of lymphoproliferative disorders, although the evidence is not always consistent. Factors such as obesity, smoking, alcohol consumption, and a diet low in fruits and vegetables have been explored as potential risk factors, but more research is needed to establish definitive links.
Immunophenotyping is a key tool in diagnosing and classifying lymphoproliferative disorders. It involves analysing the cell surface markers or antigens expressed by the abnormal lymphocytes.
Flow cytometry is commonly used to perform immunophenotyping and can help differentiate between different types of lymphocytes, assess their maturation stage, and detect abnormal populations of cells.
For example, markers such as CD19, CD20, CD3, CD5, and CD23 are used to characterise B cell and T cell lymphomas.
Lymphoproliferative disorders can affect the normal functioning of organs involved in the lymphatic system, such as lymph nodes, spleen, bone marrow, and liver.
Enlargement of these organs can lead to complications such as compression of nearby organs/tissues, impaired organ function, and disruption of normal blood cell production.
Lymphoproliferative disorders are characterised by the uncontrolled growth of abnormal lymphocytes.
Without treatment, the disease is likely to progress, leading to an increase in tumour burden and the spreading of cancerous cells to other lymph nodes, organs, or tissues.
This can result in more advanced and aggressive disease, making it more challenging to achieve effective treatment outcomes.
It's important to emphasise that individual cases can differ, and every person's prognosis should be discussed with his/her healthcare team, considering all the relevant factors.
The healthcare team can provide more specific information and personalised prognosis based on the particular lymphoproliferative disorder and the individual's unique circumstances.
Non-Hodgkin lymphoma is a diverse group of lymphomas, and its incidence varies by subtype and geographical location.
Globally, NHL is one of the most common cancers, with an estimated incidence of around 3 to 4 cases per 100,000 people per year.
No, lymphoproliferative disorder is not completely curable. However, there are various clinical treatments available for which patients can sign up to see if it is making a difference or not.
The survival rates for NHL can vary widely depending on the subtype and stage of the disease.
Overall, the 5-year relative survival rate for NHL is approximately 71% in the United States, according to the American Cancer Society.
Yes, lymphoproliferative disorders can come back or relapse after treatment.
The possibility of recurrence depends on several factors, including the type and stage of the lymphoproliferative disorder, the individual's response to treatment, and other patient-specific factors.
The 10-year survival rate is one way to measure long-term outcomes, but it's important to remember that each case is unique, and survival rates can differ for every individual.
The 10-year survival rate for lymphoproliferative disorder varies depending on the subtype and stage of the disease. Overall, the 10-year relative survival rate for NHL in the United States is 59%.
Myth: Lymphoproliferative disorders are always fatal.
Fact: While some lymphoproliferative disorders can be aggressive and have a poor prognosis, not all cases are fatal. The outlook and treatment options vary depending on the specific subtype, stage of the disease, individual patient factors, and response to treatment. Many individuals with lymphoproliferative disorders, including certain types of lymphoma and leukaemia, can manage their condition with appropriate treatment and ongoing care.
Myth: Only older individuals get lymphoproliferative disorders.
Fact: Although the risk of developing lymphoproliferative disorders increases with age, these disorders can occur in individuals of any age, including children and young adults. Certain types of lymphoproliferative disorders, such as Hodgkin's lymphoma, have a bimodal age distribution, with peaks in young adulthood and later in life. It's important to recognise that lymphoproliferative disorders can affect individuals across different age groups.
Myth: Lymphoproliferative disorders always cause noticeable symptoms.
Fact: While some individuals with lymphoproliferative disorders experience symptoms such as enlarged lymph nodes, fever, night sweats, and fatigue, not all cases display obvious signs. Some individuals may have no symptoms or only mild and nonspecific complaints. Regular medical check-ups and diagnostic tests are important for early detection and accurate diagnosis of lymphoproliferative disorders, even in the absence of apparent symptoms.
All the articles on HexaHealth are supported by verified medically-recognized sources such as; peer-reviewed academic research papers, research institutions, and medical journals. Our medical reviewers also check references of the articles to prioritize accuracy and relevance. Refer to our detailed editorial policy for more information.
Last Updated on: 17 July 2023
MBBS, DNB General Surgery, Fellowship in Minimal Access Surgery, FIAGES
12 Years Experience
Dr Aman Priya Khanna is a well-known General Surgeon, Proctologist and Bariatric Surgeon currently associated with HealthFort Clinic, Health First Multispecialty Clinic in Delhi. He has 12 years of experience in General Surgery and worke...View More
MSc. Clinical Research I PG Diploma in Public Health Services Management
3 Years Experience
His work in medical content writing and proofreading is noteworthy. He has also contributed immensely to public health research and has authored four scientific manuscripts in international journals. He was assoc...View More
Book Consultation
Latest Health Articles